A5034854878- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Eosinophilic Disorders and Syndromes
- CAR-T cell therapy research
- Herpesvirus Infections and Treatments
- Immune Cell Function and Interaction
- Click Chemistry and Applications
- Poxvirus research and outbreaks
- Chemotherapy-induced cardiotoxicity and mitigation
- Viral-associated cancers and disorders
- Platelet Disorders and Treatments
- Protein Tyrosine Phosphatases
- Food Allergy and Anaphylaxis Research
- Viral Infectious Diseases and Gene Expression in Insects
- Bat Biology and Ecology Studies
- Species Distribution and Climate Change
- Acute Lymphoblastic Leukemia research
- Bartonella species infections research
- HER2/EGFR in Cancer Research
- Renal Diseases and Glomerulopathies
- Dermatology and Skin Diseases
- Wildlife Ecology and Conservation
- Virus-based gene therapy research
Centre d'Écologie Fonctionnelle et Évolutive
2025
Centre Hospitalier Universitaire de Montpellier
2009-2024
Centre Léon Bérard
2023-2024
Hôpital Saint Eloi
2024
Centre Hospitalier de Versailles
2024
Université de Montpellier
2023
Université de Nîmes
2022
<h3>Importance</h3> Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. <h3>Objective</h3> To assess the efficacy and adverse event profile of in immunocompromised HSCT recipients. <h3>Design, Setting, Participants</h3> Phase 3, randomized, observer-blinded study conducted 167 centers 28...
CD19-directed CAR T-cells have been remarkably successful in treating patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and transformed follicular (t-FL). In this cohort study, we treated 60 axicabtagene ciloleucel or tisagenlecleucel. Complete partial metabolic responses (CMR/PMR) were obtained 40% 23% of patients, respectively. After 6.9 months median follow-up, progression-free survival (mPFS) overall (mOS) estimated at 3.1 12.3 months, Statistical analyses...
Advance in the phenology of plants and animals is second rule biodiversity responses to climate change. The magnitude observed changes is, however, very variable across species. Several biological factors could influence strength phenological advances, including lifestyle. Hibernation has evolved response harsh environmental conditions could, hence, potentially buffer organisms against changing climatic conditions. In Alps, alpine marmot hibernates for almost 6 months. During that time...
Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) untreated RT of diffuse large B-cell histology (NCT03931642). In this multicentre phase 2 study, without complete response (CR) two cycles were eligible to receive 8-week induction via continuous vein infusion stepwise...
Summary This prospective, observational study enrolled 150 adult patients with chronic myeloid leukaemia ( CML ) in phase CP treated nilotinib as second‐line after imatinib, a real life setting France. Two‐thirds of switched to treatment due lack imatinib efficacy. Of 146 evaluable patients, 16 (11·0%) (95% confidence interval: 6·4–17·2%) achieved uMR 4 , defined undetectable molecular disease cDNA MR sensitivity (≥10 000 ABL 1 transcripts) at 18 months and confirmed 24 (primary endpoint)....
Summary The TOPASE study was set up to evaluate the outcomes of chronic myeloid leukaemia [CML] patients treated with ponatinib (PON) in a real‐world setting France. One hundred and twenty CML patients, 105 phase (CP), 8 accelerated (AP) 7 blastic (BP) were included. Fifty‐one (49%) CP‐CML third line treatment. trigger for PON initiation ‘poor response’ 67 tolerance’ 28 ‘response enhancement’ seven patients. median dose at 30 mg/day [Q1; Q3 = 15; 30] 45 30; 45] AP/BP‐CML. Of 98 evaluable 72...